Elevation of the plasma Aβ40/Aβ42 ratio as a diagnostic marker of sporadic early-onset Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 48, Issue 4, 2015, Pages 1043-1050

  Kim, Hyeong Jun ^a   Park, Kyung Won ^b   Kim, Tae Eun ^a   Im, Ji Young ^a   Shin, Ho Sik ^a   Kim, Saeromi ^a   Lee, Dong Hyun ^a   Ye, Byoung Seok ^c   Kim, Jong Hun ^d   Kim, Eun Joo ^e   Park, Kee Hyung ^f   Han, Hyun Jeong ^g   Jeong, Jee Hyang ^h   Choi, Seong Hye ⁱ   Park, Sun Ah ^a  

^a Soonchunhyang University   (South Korea)

^b Dong A University College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d National Health Insurance Corporation   (South Korea)

^e Pusan National University School of Medicine   (South Korea)

^f Gachon University   (South Korea)

^g Seonam University   (South Korea)

^h Ewha Womans University   (South Korea)

ⁱ Inha University School of Medicine   (South Korea)

Author keywords

Alzheimer's disease; amyloid protein; biomarker; blood brain barrier; plasma

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; ALBUMINOID; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E4; PEPTIDE FRAGMENT; SERUM ALBUMIN;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; APOLIPOPROTEIN E EPSILON4 GENE; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPORADIC EARLY ONSET ALZHEIMER DISEASE; AREA UNDER THE CURVE; BLOOD; CAPILLARY PERMEABILITY; GENETICS; METABOLISM; MIDDLE AGED; ONSET AGE;

AGE OF ONSET; AGED; ALBUMINS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; AREA UNDER CURVE; BIOMARKERS; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDE FRAGMENTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN;

EID: 84946084657     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-143018     Document Type: Article

References (48)

1. Jack CR Jr, Holtzman DM. (2013). Biomarker modeling of Alzheimer's disease. Neuron. 80, 1347-1358.
2. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, De Kosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. (2014). Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. Lancet Neurol. 13, 614-629.
3. Mayeux R, Schupf N. (2011). Blood-based biomarkers for Alzheimer's disease: Plasma Abeta40 and Abeta42, and genetic variants. Neurobiol Aging 32(Suppl 1), S10-S19.
4. Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, Jack CR Jr, Jagust W, De carli C, Toga AW, Toledo E, Xie SX, Lee VM, Trojanowski JQ, Shaw LM. (2011). Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 122, 401-413.
5. Song F, Poljak A, Valenzuela M, Mayeux R, Smythe GA, Sachdev PS. (2011). Meta-Analysis of plasma amyloid-beta levels in Alzheimer's disease. J Alzheimers Dis. 26, 365-375.
6. Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F. (2012). Plasma amyloid-beta as a predictor of dementia and cognitive decline: Asystematic reviewand meta-Analysis. Arch Neurol. 69, 824-831.
7. Querfurth HW, LaFerla FM. (2010). Alzheimer's disease. N Engl J Med. 362, 329-344.
8. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. (2011). The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers De ment 7, 263-269.
9. Toledo JB, ShawLM, Trojanowski JQ. (2013). Plasma amyloid beta measurements - A desired but elusive Alzheimer's disease biomarker. Alzheimers Res Ther 5, 8.
10. Rembach A, Watt AD, Wilson WJ, Villemagne VL, Burnham SC, Ellis KA, Maruff P, Ames D, Rowe CC, Macaulay SL, Bush AI, Martins RN, Masters CL, Doecke JD. (2014). Plasma amyloid-beta levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden. J Alzheimers Dis. 40, 95-104.
11. Chen M, Inestrosa NC, Ross GS, Fernandez HL. (1995). Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun. 213, 96-103.
12. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP. (2001). Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett. 304, 102-106.
13. Wilson MR, Yerbury JJ, Poon S. (2008). Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Mol Biosyst 4, 42-52.
14. Metti AL, Cauley JA, Ayonayon HN, Harris TB, Rosano C, Williamson JD, Yaffe K. (2013). The demographic and medical correlates of plasma abeta40 and abeta42. Alzheimer Dis Assoc Disord. 27, 244-249.
15. Schneider JA, Arvanitakis Z, Leurgans SE, BennettDA(2009) The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 66, 200-208.
16. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD. (2003). Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: Relation to age, mortality, and risk. Neurology. 61, 1185-1190.
17. Davidson YS, Raby S, Foulds PG, Robinson A, Thompson JC, Sikkink S, Yusuf I, Amin H, DuPlessis D, Troakes C, Al-Sarraj S, Sloan C, Esiri MM, Prasher VP, Allsop D, Neary D, Pickering-Brown SM, Snowden JS, Mann DM. (2011). TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: Association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol. 122, 703-713.
18. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P,Wiste HJ,Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. (2013). Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207-216.
19. Bettens K, Sleegers K, Van Broeckhoven C. (2010). Current status on Alzheimer disease molecular genetics: From past, to present, to future. Hum Mol Genet. 19, R4-R11.
20. Park HK, Choi SH, Park SA, Kim HJ, LeeY, Han SH, Kim EJ, Kim BC, Han HJ, Moon SY, Yang DW, Park KW, Park KH, Yoon B, Seo SW, Na DL, Na HR, Lee JH. (2015). Cognitive profiles and neuropsychiatric symptoms inKorean early-onset Alzheimer's disease patients: ACREDOS study. J Alzheimers Dis. 44, 661-673.
21. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J. (1992). Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: Diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 55, 967-972.
22. Noh Y, Lee Y, Seo SW, Jeong JH, Choi SH, Back JH, Woo SY, Kim GH, Shin JS, Kim CH, Cho H, Park JS, Lee JM, Hong CH, Kim SY, Lee JH, Park KH, Han SH, Cheong HK, Na DL. (2014) A new classification system for ischemia using a combination of deep and periventricular white matter hyperintensities. J Stroke Cerebrovasc Dis. 23, 636-642.
23. Park SA, Kim JH, Kim HJ, Kim TE, Kim YJ, Lee DH, Park JH, Chae WS, Yim SJ, Seo SW, Na DL, Choi SH. (2013). Preliminary study for a multicenter study of Alzheimer's disease cerebrospinal fluid biomarkers. De ment Neurocognitive Disord. 12, 1-8.
24. Park HK, Na DL, Lee JH, Kim JW, Ki CS. (2008). Identification of PSEN1 and APP gene mutations in Korean patients with early-onset Alzheimer's disease. J Korean Med Sci. 23, 213-217.
25. Wada H. (1998). Blood-brain barrier permeability of the demented elderly as studied by cerebrospinal fluid-serum albumin ratio. Intern Med. 37, 509-513.
26. Algotsson A, Winblad B. (2007). The integrity of the bloodbrain barrier in Alzheimer's disease. Acta Neurol Scand. 115, 403-408.
27. Bachmeier C, Paris D, Beaulieu-Abdelahad D, Mouzon B, Mullan M, Crawford F. (2013) A multifaceted role for apoE in the clearance of beta-Amyloid across the blood-brain barrier. Neurodegener Dis. 11, 13-21.
28. Sharman MJ, Morici M, Hone E, Berger T, Taddei K, Martins IJ, Lim WL, Singh S, Wenk MR, Ghiso J, Buxbaum JD, Gandy S, MartinsRN(2010)APOEgenotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice. J Alzheimers Dis. 21, 403-409.
29. Silverberg GD, Messier AA, Miller MC, Machan JT, Majmudar SS, Stopa EG, Donahue JE, Johanson CE. (2010). Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J Neuropathol Exp Neurol. 69, 1034-1043.
30. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, Quadri P, Forloni G, Mariani C. (2006). Plasma levels of beta-Amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 27, 904-905.
31. Lui JK, Laws SM, Li QX,Villemagne VL, Ames D, Brown B, Bush AI, De Ruyck K, Dromey J, Ellis KA, Faux NG, Foster J, Fowler C, Gupta V, Hudson P, Laughton K, Masters CL, Pertile K, Rembach A, Rimajova M, Rodrigues M, Rowe CC, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B,Ward V, Martins RN, Group AR. (2010). Plasma amyloid-beta as a biomarker in Alzheimer's disease: The AIBL study of aging. J Alzheimers Dis. 20, 1233-1242.
32. Chouraki V, Beiser A, Younkin L, Preis SR, Weinstein G, Hansson O, Skoog I, Lambert JC, Au R, Launer L, Wolf PA, Younkin S, Seshadri S. (2015). Plasma amyloid-beta and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimers De ment. 11, 249-257.
33. Wang T, Xiao S, Liu Y, Lin Z, Su N, Li X, Li G, Zhang M, Fang Y. (2014). The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease. Int J Geriatr Psychiatry. 29, 713-719.
34. Lambert JC, Schraen-Maschke S, Richard F, FievetN, Rouaud O, Berr C, Dartigues JF, Tzourio C, Alperovitch A, Buee L, Amouyel P. (2009). Association of plasma amyloid beta with risk of dementia: The prospective Three-City Study. Neurology. 73, 847-853.
35. Okereke OI, Xia W, Selkoe DJ, Grodstein F. (2009). Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol. 66, 1247-1253.
36. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM(2006) Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: A prospective case-cohort study. Lancet Neurol. 5, 655-660.
37. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG. (2007). Association of lowplasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 64, 354-362.
38. Takeda S, Sato N, Rakugi H, Morishita R. (2010). Plasma beta-Amyloid as potential biomarker of Alzheimer disease: Possibility of diagnostic tool for Alzheimer disease. Mol Biosyst 6, 1760-1766.
39. Tate J, Ward G. (2004). Interferences in immunoassay. Clin Biochem Rev. 25, 105-120.
40. Vanderstichele H, Stoops E, Vanmechelen E, Jeromin A. (2012). Potential sources of interference on Abeta immunoassays in biological samples. Alzheimers Res Ther 4, 39.
41. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV. (2000). Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 106, 1489-1499.
42. De Mattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. (2002). Brain to plasma amyloid-beta efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 295, 2264-2267.
43. De ane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E,Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. (2003). RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9, 907-913.
44. De ane R,Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, HuHW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV. (2004). LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 43, 333-344.
45. Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Bürger K, Hampel H, Frölich L, Henn F, Falkai P, Rüther E, Jahn H, Luckhaus Ch, Perneczky R, Schmidtke K, Schröder J, Kessler H, Pantel J, Gertz HJ, Vanderstichele H, de Meyer G, Shapiro F, Wolf S, Bibl M, Wiltfang J. (2010). Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Exp Neurol. 223, 366-370.
46. HuangY, Potter R, SigurdsonW, Kasten T, Connors R, Morris JC, Benzinger T, Mintun M, Ashwood T, Ferm M, Budd SL, Bateman RJ. (2012). beta-Amyloid dynamics in human plasma. Arch Neurol. 69, 1591-1597.
47. Le Bastard N, Aerts L, Leurs J, Blomme W, De De yn PP, Engelborghs S. (2009). No correlation between time-linked plasma and CSF Abeta levels. Neurochem Int. 55, 820-825.
48. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K. (2010). Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging. 31, 357-367.